Structural insights for selective disruption of Beclin 1 binding to Bcl-2

Stimulation of autophagy could provide powerful therapies for multiple diseases, including cancer and neurodegeneration. An attractive drug target for this purpose is Bcl-2, which inhibits autophagy by binding to the Beclin 1 BH3-domain. However, compounds that preclude Beclin 1/Bcl-2 binding might also induce apoptosis, which is inhibited by binding of Bcl-2 to BH3-domains of pro-apoptosis factors such as Bax. Here we describe the NMR structure of Bcl-2 bound to 35, a compound that we recently found to inhibit Beclin 1/Bcl-2 binding more potently than Bax/Bcl-2 binding. The structure shows that 35 binds at one end of the BH3-binding groove of Bcl-2. Interestingly, much of the 35-binding site is not involved in binding to Bcl-2 inhibitors described previously and mediates binding to Beclin 1 but not Bax. The structure suggests potential avenues to design compounds that disrupt Beclin 1/Bcl-2 binding and stimulate autophagy without inducing apoptosis. The NMR structure of Bcl-2 bound to a recently discovered inhibitor reveals a binding site that may provide the possibility of selectively disrupting binding of Bcl-2 to Beclin 1.

Automated summary

Stimulation of autophagy through targeting Bcl-2 binding could be a potential therapy for various diseases. This study describes the NMR structure of Bcl-2 bound to a compound that inhibits Beclin 1/Bcl-2 binding more effectively than Bax/Bcl-2 binding. The structure suggests the possibility of designing compounds that disrupt Beclin 1/Bcl-2 binding and stimulate autophagy without inducing apoptosis.